Researchers have focused a lot of attention on protein degradation targeting chimeras (also known as proteolysis targeting chimeras, or PROTACs) because they can effectively break down proteins to treat a variety of diseases. Traditional PROTAC small molecules, while promising, exhibit poor pharmacokinetic behavior and lack tumor specificity. Its continuous high-efficiency catalytic degradation characteristics will uncontrollably break down POI proteins in normal tissue sites, causing serious toxic and side effects that severely restrict its clinical application.
Therefore, the precise delivery of PROTAC molecules to tumor sites and the effective degradation of intratumoral target proteins are crucial for the development of PROTAC antitumor drugs.
Researchers Yu Haijun from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Professor Xu Huixiong from Zhongshan Hospital Affiliated to Fudan University, and Professor Xu Zhiai from East China Normal University published a research paper titled "Engineered bioorthogonal POLY-PROTAC nanoparticles for tumor-specific protein degradation" in the journal Nature Communications on July 26, 2022.
This study innovatively proposed a polymerized PROTAC (POLY-PROTAC) nano-therapeutic strategy based on the early development of a variety of tumor microenvironment-responsive intelligent drug delivery systems by Yu Haijun's group, which achieved tumor-specific PROTAC delivery and protein degradation. The research results demonstrate the precise degradation of target proteins by POLY-PROTAC and the prospect of efficient tumor treatment based on PROTAC.
To achieve precise tumor delivery of PROTACs, the research team first synthesized a series of small-molecule PROTACs based on von Hipel-Lindau (VHL) ligands. The disulfide-modified precursor PROTACs were then attached to the amphiphilic polymer by covalent reversible addition-fragmentation chain transfer (RAFT).
The high molecular polymer can self-assemble to form uniform and stable nanoparticles and has responsiveness to tumor extracellular enzyme environment, intracellular acid environment, and reducing environment so that the nanoparticles can achieve specific aggregation and efficient penetration of tumor tissue.
In addition, the research team carried out azide modification on the nanoparticles to further increase the accumulation and retention of nanoparticles in tumor tissue through a bioorthogonal strategy. To this end, the research team designed pre-targeted nanoparticles loaded with DBCO groups in response to the slightly acidic environment of tumor cells, which can dissociate and expose DBCO groups in a slightly acidic environment outside the tumor cells, thereby capturing azide-modified POLY-PROTAC nanoparticles through click chemistry.
The research team demonstrated that the bioorthogonal POLY-PROTAC nanoparticles combined with photodynamic therapy can effectively activate the apoptotic protein caspase-3, thereby achieving high-efficiency anti-tumor effects. This research result proposes a general nanoplatform for the specific delivery of PROTAC molecules to tumor sites and confirms its antitumor potential.
According to the report published by Allied Market Research, the global biotech ingredients market was pegged at $51.3 billion in 2020 and is estimated to hit $75.3 billion by 2028, registering a CAGR of 4.8% from 2021 to 2028.
The report provides an in-depth analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends.Shift in consumer preference from synthetic to bio-based ingredients and development in biotechnology fuel the growth of the global biotech ingredients market.
On the other hand, limited availability of raw materials restrains the growth to some extent.
However, favorable government policies and technological advancements in bio-engineering are expected to create lucrative opportunities in the industry.Request PDF Brochure: https://www.alliedmarketresearch.com/request-sample/11710COVID-19 scenario-The outbreak of the pandemic has given way to either closure or suspension of production activities in most industrial units across the globe, which has impacted the market negatively.Nevertheless, initiation of mass vaccination in most countries is projected to mend the global situation and market is expected to get back on track soon.The global biotech ingredients market is analyzed across type, product, expression systems, and region.
The biosimilars segment, on the other hand, would exhibit the fastest CAGR of 5.0% during the forecast period.Based on product, the monoclonal antibodies segment contributed to more than one-fifth of the total market revenue in 2020 and is expected to dominate by 2028.
However, the hormones and growth factors segment would cite the fastest CAGR of 5.5% during from 2021 to 2028.Get Detailed COVID-19 Impact Analysis on the Biotech Ingredients Market: https://www.alliedmarketresearch.com/request-for-customization/11710?reqfor=covidBased on region, Europe held the major share in 2020, garnering nearly two-fifths of the global market.
